Skip to main content
< Back to news
Olivier Corminboeuf and Blandine Guimet. Photo / Nuage Therapeutics
 31.07.2025

Nuage Therapeutics welcomes Olivier Corminboeuf and Blandine Guimet to their Leadership Team

The biotech company Nuage Therapeutics, based at the Barcelona Science Park, continues to grow with the addition of Olivier Corminboeuf and Blandine Guimet to its leadership team. Their leadership will be key in the new phase of development for this spin-off of the Institute for Research in Biomedicine (IRB Barcelona), which is focused on overcoming the limits of traditionally intractable therapeutic targets, such as intrinsically disordered proteins (IDPs), implicated in serious diseases like cancer. The company aims to unlock the therapeutic potential of these proteins and drive a new generation of transformative treatments.

Olivier Corminboeuf joins Nuage Therapeutics as Head of Drug Discovery. Prior to this, he served as Head of Medicinal Chemistry at Idorsia. Olivier brings extensive expertise in medicinal chemistry from his roles at both Idorsia and Actelion, with a particular focus on oncology and immunology. Over the course of his career, Olivier has contributed to the discovery of multiple drug candidates that have progressed into clinical development.

“I’m thrilled to join Nuage Therapeutics at such an exciting moment. Nuage is pioneering a disruptive platform that redefines what’s possible in drug discovery—by turning intrinsically disordered proteins (IDPs), long considered undruggable, into druggable therapeutic targets. This breakthrough opens entirely new avenues for precision medicine, and I look forward to helping advance Nuage’s pipeline to bring impactful therapies to patients”, affirms Corminboeuf.

Meanwhile, Blandine Guimet steps into the role of Head of People. Blandine has extensive expertise in Human Resources, gained through operational and strategic roles within corporate and start-ups environments. In 2021, Blandine founded Start HR Consulting, a company that provides support to biotech companies with their HR needs through their early and growth phases. Blandine holds an MA in Human Resources Management and is certified in co-active coaching.

“It’s a real pleasure to be part of Nuage Therapeutics’ journey at such a key moment. I’m looking forward to helping build the foundations that will support our teams as we grow — through strong, scalable people practices and a culture where everyone feels empowered, supported, and inspired to do their best work”, explains Guimet.

The company highlights the importance of these two new additions in continuing its trajectory of growth, evolution, and boundary-pushing — paving the way for a new generation of transformative therapies by harnessing the ability to modulate intrinsically disordered proteins (IDPs).

» Link to the news: Nuage Therapeutics website [+]